GRFS vs LKFT
Grifols SA and Lakefront Biotherapeutics NV, side by side — 10 fiscal years reported in EUR, drawn from SEC filings.
Most recent reported year
| Metric | GRFS | LKFT |
|---|---|---|
| Revenue | €7.2B | €1.1B |
| Net income | €156.9M | €320.9M |
| Gross margin | 38.7% | 97.3% |
| Net margin | 3.0% | 28.9% |
| Return on equity | 2.8% | 10.5% |
| Diluted EPS | €0.23 | €4.87 |
| Dividend / share | · | · |
| Payout ratio | 0.6% | · |
| Free cash flow | €669.6M | €-271.2M |
| Equity | €5.9B | · |
| Net debt / equity | · | · |
| Current ratio | 2.66× | 20.15× |
| Revenue CAGR 5y | 7.2% | 18.4% |
| Profit CAGR 5y | −24.2% | · |
GRFS bills 6.5× the revenue of LKFT, and LKFT keeps more of each dollar of revenue as profit (28.9% against 3.0%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | GRFS | LKFT |
|---|---|---|
| FY2024 | €7.2B | €275.6M |
| FY2023 | €6.6B | €239.7M |
| FY2022 | €6.1B | €241.2M |
| FY2021 | €4.9B | €234.4M |
| FY2020 | €5.3B | €478.1M |
| FY2019 | €5.1B | €834.9M |
| FY2018 | €4.5B | €278.7M |
| FY2017 | €4.3B | €127.1M |
| FY2016 | €4.0B | €129.5M |
| FY2015 | €3.9B | €39.6M |
Bottom line
| Fiscal year | GRFS | LKFT |
|---|---|---|
| FY2024 | €156.9M | €74.1M |
| FY2023 | €42.3M | €211.7M |
| FY2022 | €185.0M | €-218.0M |
| FY2021 | €188.7M | €-103.2M |
| FY2020 | €618.5M | €-305.4M |
| FY2019 | €625.1M | €149.8M |
| FY2018 | €596.6M | €-29.3M |
| FY2017 | €662.7M | €-115.7M |
| FY2016 | €545.5M | €54.0M |
| FY2015 | €532.1M | €-118.4M |
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2024 | +€6,936,733,000 | GRFS |
| FY2023 | +€6,352,253,000 | GRFS |
| FY2022 | +€5,822,718,000 | GRFS |
| FY2021 | +€4,698,734,000 | GRFS |
| FY2020 | +€4,861,985,000 | GRFS |
| FY2019 | +€4,263,790,000 | GRFS |
| FY2018 | +€4,208,058,000 | GRFS |
| FY2017 | +€4,190,986,000 | GRFS |
| FY2016 | +€3,920,311,000 | GRFS |
| FY2015 | +€3,895,000,000 | GRFS |
GRFS has reported the higher revenue in every one of these 10 fiscal years. The gap has widened since the earliest year compared.
10 of 11 comparable fiscal years — a year missing data on either side is not counted.
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2024 | −23.9 pp | LKFT |
| FY2023 | −85.8 pp | LKFT |
| FY2022 | +94.4 pp | GRFS |
| FY2021 | +49.4 pp | GRFS |
| FY2020 | +77.2 pp | GRFS |
| FY2019 | −5.2 pp | LKFT |
| FY2018 | +23.7 pp | GRFS |
| FY2017 | +106.4 pp | GRFS |
| FY2016 | −28.3 pp | LKFT |
| FY2015 | +312.8 pp | GRFS |
The higher net margin has changed hands between GRFS and LKFT over this period.
10 of 11 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
LKFT's net margin has been more volatile than GRFS's over the 10 comparable fiscal years — 102.3 percentage points of standard deviation against 4.9.
10 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between GRFS and LKFT over these 10 fiscal years — GRFS led in 6 and LKFT in 4.
10 of 11 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
LKFT's return on equity has been more volatile than GRFS's over the 10 comparable fiscal years — 12.1 percentage points of standard deviation against 6.4.
10 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between GRFS and LKFT over these 10 fiscal years — GRFS led in 9 and LKFT in 1.
10 of 11 comparable fiscal years — a year missing data on either side is not counted.